Maxemiliano Vargas

Ph.D. alumnus in Neuroscience at UC Davis; researcher in the Institute for Psychedelics and Neurotherapeutics

Data updated

Papers

6 publications

Trials

0 clinical trials

Links

Research Footprint

Maxemiliano Vargas appears in 6 tracked papers (2020–2026), most studied alongside MDMA, Psilocybin and Ketamine, across Depressive Disorders, Medicinal Chemistry & Drug Development and Opioid Use Disorder (OUD).

Most-cited paper: A non-hallucinogenic psychedelic analogue with therapeutic potential (460 citations).

Frequent co-authors: David Olson, Lee Edmunds Dunlap and Lindsay Cameron.

Background & Research

Maxemiliano Vargas is a neuroscientist associated with the University of California, Davis and the Institute for Psychedelics and Neurotherapeutics. He coauthored multiple influential papers on psychedelic-induced neuroplasticity and psychoplastogens, including studies on intracellular 5-HT2A receptor signaling and engineered biosensors for psychedelic-inspired drug discovery. UC Davis described him as a 2023 Ph.D. alumnus in neuroscience.

Key Impact

He is a key contributor to mechanistic psychedelic neuroscience, including work showing that intracellular 5-HT2A receptors mediate psychedelic-induced neuroplasticity.

6

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

5 collaborators· click a node to visit their profile

Full network →

Affiliations

Institutions, companies, and organisations Maxemiliano Vargas is associated with.